ScienceMedia, a global SaaS provider redefining the landscape of clinical mastery in the biotech and pharma industries, announces the formation of its inaugural advisory board. The powerhouse team of six esteemed industry pioneers shares a vision for revolutionizing clinical trials and science education, bringing a broad set of business management skills and vision for innovation within the field.
Mark Surles, CEO of ScienceMedia, shares, "Tasked with guiding the evolution of ScienceMedia's product development portfolio, these luminaries will play a pivotal role in identifying industry gaps and shaping strategic initiatives to drive business growth." Surles emphasized the importance of assembling a board with profound understanding and experience across clinical trial operations at the sponsor, foundation, CRO, and site levels, as well as in product innovation, rare disease, and patient advocacy
" Surles emphasized the importance of assembling a board with profound understanding and experience across clinical trial operations at the sponsor, foundation, CRO, and site levels, as well as in product innovation, rare disease, and patient advocacy
Mark Surles, CEO of ScienceMedia, shares, "Tasked with guiding the evolution of ScienceMedia's product development portfolio, these luminaries will play a pivotal role in identifying industry gaps and shaping strategic initiatives to drive business growth." Surles emphasized the importance of assembling a board with profound understanding and experience across clinical trial operations at the sponsor, foundation, CRO, and site levels, as well as in product innovation, rare disease, and patient advocacy
" Surles emphasized the importance of assembling a board with profound understanding and experience across clinical trial operations at the sponsor, foundation, CRO, and site levels, as well as in product innovation, rare disease, and patient advocacy
ScienceMedia's advisory board members include:
Dr. Surles expressed his enthusiasm for the future: "As we embark on what promises to be a groundbreaking year for the pharma and biotech industries, we are thrilled to enlist the expertise of these distinguished leaders to shape our path forward. Their unparalleled insights—from patient-centric approaches to cutting-edge AI advancements—will fuel our mission to drive a transformative revolution in clinical trials."
Malachi Bierstein, Chief Commercial Officer at ScienceMedia, emphasized the impact of the advisory board's insights: "This exceptional group of key opinion leaders has already proven instrumental in reframing how we discuss the complex disease and protocol education issues that ScienceMedia has been solving across patients, sites, and study teams.  Their insight will accelerate our growth and allow us to continue solving the most challenging therapeutic and clinical issues facing the industry."
ScienceMedia has catalyzed a paradigm shift in therapeutic area training and clinical mastery at the Summit for Clinical Operations Executives (SCOPE) in Orlando, Florida with the unveiling of ScienceMedia MindFlow™ that harnesses the power of multimodal learning to revolutionize knowledge retention and acquisition.
Bierstein continues, "Embracing the spirit of innovation and collaboration, our esteemed advisory board represents the vanguard of change in the pharmaceutical and biotech sectors. As we stand on the cusp of unprecedented breakthroughs, we will continue to challenge conventions and break barriers that will redefine the future of clinical trials."
For further insights into ScienceMedia's groundbreaking initiatives and the dawn of a new era in clinical mastery, click here.
_______
Visit ScienceMedia to learn more.
Contact: Jen Pfau [email protected](805) 452-1795
SOURCE ScienceMedia
ScienceMedia announces they are revolutionizing trial protocol training through the science of learning by debuting their proprietary approach,...

Source prnewswire